Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib StudyKerry A Rogers, Pearlly Yan, Ian W Flinn, et al.
Leukemia|June 25, 2026
Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse eventsAnthony G Mansour, Ying Huang, J Phillip Pemberton, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Blood|February 5, 2009
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivoDavid M Lucas, Ryan B Edwards, Gerard Lozanski, et al.
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib StudyKerry A Rogers, Pearlly Yan, Ian W Flinn, et al.
Leukemia|June 25, 2026
Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse eventsAnthony G Mansour, Ying Huang, J Phillip Pemberton, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Blood|February 5, 2009
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivoDavid M Lucas, Ryan B Edwards, Gerard Lozanski, et al.
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Pageof 14